Business Standard

Launch of inhalation product improves Lupin's revenue visibility

More US launches and uptick in the Indian market are key near-term triggers


In addition to this launch, there are other products which could drive Lupin’s revenues in the US market

Ram Prasad Sahu Mumbai
After a delay in the June quarter, Lupin finally received the go-ahead from the US drug regulator to launch the generic version of inhalation brand ProAir.  The launch of Lupin’s first device-based inhalation product for asthma will not only help it rake in sales in this limited competition segment, but also validate its capabilities in this space. While the market for inhalation chemical albuterol sulfate is just under $3 billion, the Proair segment, which Lupin is targeting, has sales of $1.3 billion. 

While there are three brands and six generic players for the drug, interchangeability among brands of the drug means

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 26 2020 | 6:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to